RT Conference Proceedings
T1 Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
A1 Carabante-Ocón, F
A1 Saez-Lara, E
A1 Burgos-Garcia, L
A1 Villar-Chamorro, E
A1 Casaus-Hazañas, A
A1 Luna, S
A1 Martínez, C
K1 trastuzumab
K1 her2-positive
K1 chemotherapies
K1 MBC
K1 neoplasias de la mama
K1 Retratamiento
AB Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherapeutic agents in the treatment for Her2+ metastatic breast cancer (MBC) patients after progression on prior trastuzumab therapy.
PB BioMed Central
SN 1465-5411
YR 2007
FD 2007-06-19
LK http://hdl.handle.net/10668/804
UL http://hdl.handle.net/10668/804
LA en
NO Carabante-Ocón  F, Saez-Lara E, Burgos-Garcia L, Villar-Chamorro E, Casaus-Hazañas A. Luna S, et al. Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study. Breast Cancer Research. 2007 Jun;9 Supplement 1:s17-8
DS RISalud
RD Apr 12, 2025